Endoplasmic reticulum-localized TurboID-mediated labelling reveals distinct secretome profiles of MCF-10A and MDA-MB-231 cells

Öz

Breast cancer is one of the most prevalent cancers and the leading causes of cancer-related deaths. The lack of reliable biomarkers for accurate subtyping and early diagnosis continues to hinder early detection and treatment. Secretome proteins represent an accessible and valuable source of biomarkers due to their roles in cell communication, signalling and shaping the extracellular microenvironment. In this study, secretome proteins from two cell lines, MCF-10A and MDA-MB-231, representing healthy and aggressive breast cells, respectively, were labelled with ER-localized TurboID-mediated enzymatic biotinylation approach at the endoplasmic reticulum. The biotinylated samples were enriched using streptavidin-coated magnetic beads and analysed by label-free quantitation using nHPLC LC-MS/MS. The regulated proteins were subjected to bioinformatics analyses using STRING and g:Profiler tools to identify candidate biomarkers. Proteomic analysis identified 206 proteins, with approximately 82% belonged to secretome proteins. Among them, 65 were differentially regulated which were associated with hydrolytic activity, cell adhesion, and lipid metabolism. CST1, APOC1, and POSTN had previously been associated with cancer, while TEX10, LZIC, and PSMA3 were implicated in breast cancer for the first time. Our findings demonstrates extensive secretome remodelling in invasive breast cancer cells, unveiling potential secreted biomarker candidates that may improve breast cancer diagnosis and treatment strategies.

Anahtar Kelimeler

• Breast cancer
• secretome
• biomarkers
• biotinylation

Endoplazmik retikuluma lokalize edilen TurboID aracılı işaretleme ile MCF-10A ve MDA-MB-231 hücrelerine ait sekretom profillerinin belirlenmesi

Öz

Meme kanseri, insidansı en yüksek olan kanser türlerinden biri olup, kanser kaynaklı ölümlerin başlıca nedenleri arasındadır. Alt tiplerin doğru sınıflandırılması ve erken tanı için güvenilir biyobelirteçlerin eksikliği, hastalığın erken teşhis ve tedavisini güçleştirmektedir. Hücre iletişimi, sinyal iletimi ve hücre dışı mikroçevrenin şekillenmesindeki rolleri nedeniyle sekretom proteinleri, biyobelirteç keşfi açısından erişilebilir ve değerli bir kaynaktır. Bu çalışmada, sağlıklı (MCF-10A) ve invaziv (MDA-MB-231) meme epitel hücre hatlarının sekretom proteinleri, endoplasmik retikuluma-lokalize edilen TurboID biyotin ligaz aracılı enzimatik biyotinilasyon yöntemiyle işaretlenmiştir. Etiketlenen proteinler streptavidin-kaplı manyetik boncuklar yardımı ile zenginleştirildikten sonra, etiketsiz miktar tayini için nHPLC LC-MS/MS yöntemi ile analiz edilmiştir. Anlamlı regülasyon gösteren proteinler STRING ve g:Profiler araçlarıyla biyoinformatik analizlere tabi tutulara biyobelirteç adayları belirlenmeye çalışılmıştır. Analizler sonucu toplam 206 protein tanımlanmış olup, bunların yaklaşık %82’si sekretom proteinleri içerine dahildir. Belirlenen bu proteinlerin 65 tanesinin gruplar arasında anlamlı farklılık gösterdiği ve bunların özellikle hidrolitik aktivite, hücre adezyonu ve lipid metabolizmasıyla ilişkili olduğu belirlenmiştir. Bu proteinlerden; CST1, APOC1 ve POSTN daha önce kanserle ilişkilendirilmişken, TEX10, LZIC ve PSMA3 ilk kez meme kanseriyle ilişkilendirilmiştir. Bulgularımız, invaziv meme kanseri hücrelerinde kapsamlı bir sekretom analizini ortaya koymuş ve meme kanseri tanı ve tedavi stratejilerini kullanılabilecek biyobelirteç adaylarının potansiyelleri sekretom düzeyinde değerlendirilmiştir.

Anahtar Kelimeler

• Meme kanseri
• sekretom
• biyomarker
• biyotinilasyon

Kaynakça

1. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A., Global cancer statistic 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: a cancer journal for clinicians, 74:229-263, (2024).
2. Chen S., Cao Z., Prettner K., Kuhn M., Yang J., Jiao L., Wang Z., Li W., Geldsetzer P., Bärnighausen T., Bloom D.E., Wang C., Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050, JAMA Oncology, 9:465-472, (2023).
3. Wilkinson L., Gathani T., Understanding breast cancer as a global health concern, British Journal of Radiology, 95:20211033, (2022).
4. Shiovitz S., Korde L.A., Genetics of breast cancer: a topic in evolution, Annals of Oncology, 26:1291-1299, (2015).
5. Sun Y.S., Zhao Z., Yang Z.N., Xu F., Lu H.J., Zhu Z.Y., Shi W., Jiang J., Yao P.P., Zhu H.P., Risk Factors and Preventions of Breast Cancer, International Journal of Biological Sciences, 13:1387-1397, (2017).
6. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A., Cancer statistics, 2022, CA: A Cancer Journal for Clinicians, 72:7-33, (2022).
7. Iqbal N., Iqbal N., Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications, Molecular Biology International, 2014:852748, (2014).
8. Ahmad A., Imran M., Ahsan H., Biomarkers as Biomedical Bioindicators: Approaches and Techniques for the Detection, Analysis, and Validation of Novel Biomarkers of Diseases, Pharmaceutics, 15:1630, (2023).

9. Xue H., Lu B., Lai M., The cancer secretome: a reservoir of biomarkers, Journal of Translational Medicine, 6:52, (2008).
10. Shama A., Soni T., Jawanda I.K., Upadhyay G., Sharma A., Prabha V., The Latest Developments in Using Proteomic Biomarkers from Urine and Serum for Non-Invasive Disease Diagnosis and Prognosis, Biomarker Insights, 18:11772719231190218, (2023).
11. Liu W., Wang Q., Chang J., Bhetuwal A., Bhattarai N., Zhang F., Tang J., Serum proteomics unveil characteristic protein diagnostic biomarkers and signaling pathways in patients with esophageal squamous cell carcinoma, Clinical Proteomics, 19:18, (2022).
12. Xue C., Yang B., Fu L., Hou H., Qiang J., Zhou C., Gao Y., Mao Z., Urine biomarkers can outperform serum biomarkers in certain diseases, Urine, 5:57-64, (2023).
13. Droujinine I.A., Meyer A.S., Wang D., Udeshi N.D., Hu Y., Rocco D., McMahon J.A., Yang R., Guo J., Mu L., Carey D.K., Svinkina T., Zeng R., Branon T., Tabatabai A., Bosch J.A., Asara J.M., Ting A.Y., Carr S.A., McMahon A.P., Perrimon N., Proteomics of protein trafficking by in vivo tissue-specific labelling, Nature Communications, 12:2382, (2021).
14. Sarihan M., Kasap M., Akpinar G., Streamlined Biotinylation, Enrichment and Analysis for Enhanced Plasma Membrane Protein Identification Using TurboID and TurboID-Start Biotin Ligases, Journal of Membrane Biology, 257:91-105, (2024).
15. Cho K.F., Branon T.C., Rajeev S., Svinkina T., Udeshi N.D., Thoudam T., Kwak C., Rhee H.W., Lee I.K., Carr S.A., Ting A.Y., Split-TurboID enables contact-dependent proximity labeling in cells, Proceedings of the National Academy of Sciences of the United States of America, 117:12143-12154, (2020).
16. Rencber S.F., Yazır Y., Sarıhan M., Sezer Z., Korun Z.E.U., Ozturk A., Duruksu G., Guzel E., Akpınar G., Corakci A., Endoplasmic reticulum stress of endometrial mesenchymal stem cells in endometriosis, Tissue and Cell, 91:102544, (2024).
17. Xiong X., Zheng L.W., Ding Y., Chen Y.F., Cai Y.W., Wang L.P., Huang L., Liu C.C., Shao Z.M., Yu K.D., Breast cancer: pathogenesis and treatments, Signal Transduction and Targeted Therapy, 10:49, (2025).
18. Li J., Guan X., Fan Z., Ching L-M., Li Y., Wang X., Cao W-M., Liu D-X., Non-Invasive Biomarkers for Early Detection of Breast Cancer, Cancers, 12:2767, (2020).
19. Beutgen V.M., Shinkevich V., Pörschke J., Meena C., Steitz A.M., Pogge von Strandmann E., Graumann J., Gómez-Serrano M., Secretome Analysis Using Affinity Proteomics and Immunoassays: A Focus on Tumor Biology, Molecular & Cellular Proteomics, 23:100830, (2024).
20. Capece D., D'Andrea D., Begalli F., Goracci L., Tornatore L., Alexander J.L., Di Veroli A., Leow S.C., Vaiyapuri T.S., Ellis J.K., Verzella D., Bennett J., Savino L., Ma Y., McKenzie J.S., Doria M.L., Mason S.E., Chng K.R., Keun H.C., Frost G., Tergaonkar V., Broniowska K., Stunkel W., Takats Z., Kinross J.M., Cruciani G., Franzoso G., Enhanced triacylglycerol catabolism by carboxylesterase 1 promotes aggressive colorectal carcinoma, The Journal of Clinical Investigation, 131, (2021).
21. Staege M.S., Hesse M., Max D., Lipases and Related Molecules in Cancer, Cancer Growth and Metastasis, 3:CGM.S2816, (2010).
22. Shields D.J., Niessen S., Murphy E.A., Mielgo A., Desgrosellier J.S., Lau S.K., Barnes L.A., Lesperance J., Bouvet M., Tarin D., Cravatt B.F., Cheresh D.A., RBBP9: a tumor-associated serine hydrolase activity required for pancreatic neoplasia, Proceedings of the National Academy of Sciences of the United States of America, 107:2189-2194, (2010).
23. Stanford S.M., Bottini N., Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders, Nature Reviews Drug Discovery, 22:273-294, (2023).
24. Popova N.V., Jücker M., The Functional Role of Extracellular Matrix Proteins in Cancer, Cancers, 14, (2022).
25. Wang S., Böhnert V., Joseph A.J., Sudaryo V., Swinderman J., Yu F.B., Lyu X., Skariah G., Subramanyam V., Gilbert L.A., Goodarzi H., Lingyin L., ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway, bioRxiv, (2023).
26. Mardjuki R., Wang S., Carozza J.A., Abhiraman G.C., Lyu X., Li L., Identification of extracellular membrane protein ENPP3 as a major cGAMP hydrolase, cementing cGAMP's role as an immunotransmitter, bioRxiv, (2024).
27. Tang X., Alothaim T., Charbonneau M., Recurrent triple-negative breast cancer from cysteine deprivation loses tumorigenicity via downregulation of the CST4 signaling, Research Square, (2022).
28. Dai D.N., Li Y., Chen B., Du Y., Li S.B., Lu S.X., Zhao Z.P., Zhou A.J., Xue N., Xia T.L., Zeng M.S., Zhong Q., Wei W.D., Elevated expression of CST1 promotes breast cancer progression and predicts a poor prognosis, Journal of Molecular Medicine, 95:873-886, (2017).
29. Zhang H., Wang Y., Liu C., Li W., Zhou F., Wang X., Zheng J., The Apolipoprotein C1 is involved in breast cancer progression via EMT and MAPK/JNK pathway, Pathology - Research and Practice, 229:153746, (2022).
30. Khalafi-Nezhad A., Barazesh M., Abdollahi A., Kheiri N., Amani M., Potential of Serum ApoC1 as a Noninvasive Biomarker for Breast Cancer Detection and Prognosis: A Prospective Case-Control Study, Cancer Reports (Hoboken, N.J.), 8:e70359, (2025).
31. Bademler S., Ucuncu M.Z., Tilgen Vatansever C., Serilmez M., Ertin H., Karanlık H., Diagnostic and Prognostic Significance of Carboxypeptidase A4 (CPA4) in Breast Cancer, Biomolecules, 9, (2019).
32. Sut B.B., Keles A.İ., Prognostic and Predictive Significance of Eukaryotic Elongation Factor 1D (eEF1D) in Breast Cancer: A Potential Marker of Response to Endocrine Therapy, Oncologie, 22:147-154, (2020).
33. Rebecca V.W., Nicastri M.C., Fennelly C., Chude C.I., Barber-Rotenberg J.S., Ronghe A., McAfee Q., McLaughlin N.P., Zhang G., Goldman A.R., Ojha R., Piao S., Noguera-Ortega E., Martorella A., Alicea G.M., Lee J.J., Schuchter L.M., Xu X., Herlyn M., Marmorstein R., Gimotty P.A., Speicher D.W., Winkler J.D., Amaravadi R.K., PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer, Cancer Discovery, 9:220-229, (2019).
34. Kadalayil L., Khan S., Nevanlinna H., Fasching P.A., Couch F.J., Hopper J.L., Liu J., Maishman T., Durcan L., Gerty S., Blomqvist C., Rack B., Janni W., Collins A., Eccles D., Tapper W., Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women, Nature Communications, 8:1632, (2017).
35. He Q., Hu J., Ngo F.Y., Zhang H., He L., Huang H., Wu T., Pan Y., Yang Z., Jiang Y., Cho W.C., Cheuk W., Tse G.M., Tsang J.Y., Yang M., Zhang L., Wang X., Lo P.C., Lau C.G., Chin Y.R., Targeting TUBB2B inhibits triple-negative breast cancer growth and brain-metastatic colonization, Journal of Experimental & Clinical Cancer Research, 44:55, (2025).
36. Khalafi-Nezhad A., Barazesh M., Abdollahi A., Kheiri N., Amani M., Potential of Serum ApoC1 as a Noninvasive Biomarker for Breast Cancer Detection and Prognosis: A Prospective Case–Control Study, Cancer Reports, 8:e70359, (2025).
37. Zhu M., Liu N., Lin J., Wang J., Lai H., Liu Y., HDAC7 inhibits cell proliferation via NudCD1/GGH axis in triple-negative breast cancer, Oncology Letters, 25:33, (2023).
38. Zhang Y., Tian J., Qu C., Peng Y., Lei J., Li K., Zong B., Sun L., Liu S., Overexpression of SERPINA3 promotes tumor invasion and migration, epithelial-mesenchymal-transition in triple-negative breast cancer cells, Breast Cancer, 28:859-873, (2021).
39. Han B., Zhen F., Sun Y., Sun B., Wang H.Y., Liu W., Huang J., Liang X., Wang Y.R., Chen X.S., Li S.J., Hu J., Tumor suppressor KEAP1 promotes HSPA9 degradation, controlling mitochondrial biogenesis in breast cancer, Cell Reports, 43:114507, (2024).
40. Smirnova T., Bonapace L., MacDonald G., Kondo S., Wyckoff J., Ebersbach H., Fayard B., Doelemeyer A., Coissieux M.M., Heideman M.R., Bentires-Alj M., Hynes N.E., Serpin E2 promotes breast cancer metastasis by remodeling the tumor matrix and polarizing tumor associated macrophages, Oncotarget, 7:82289-82304, (2016).
41. Loh C.Y., Chai J.Y., Tang T.F., Wong W.F., Sethi G., Shanmugam M.K., Chong P.P., Looi C.Y., The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenge, Cells, 8, (2019).
42. Rajkumar S.D., Gunabooshanam B., Joseph L.D., D'Cruze L., Utility of immunohistochemical expression of E-cadherin in colorectal carcinoma, Prz Gastroenterol, 17:59-66, (2022).
43. Venhuizen J.H., Jacobs F.J.C., Span P.N., Zegers M.M., P120 and E-cadherin: Double-edged swords in tumor metastasis, Seminars in Cancer Biology, 60:107-120, (2020).
44. Yang F., Liu X.Q., He J.Z., Xian S.P., Yang P.F., Mai Z.Y., Li M., Liu Y., Zhang X.D., Occludin facilitates tumour angiogenesis in bladder cancer by regulating IL8/STAT3 through STAT4, Journal of Cellular and Molecular Medicine, 26:2363-2376, (2022).
45. Shirkoohi R., Ghoojaei M., Saffari M., Emamirazavi A., Hashemi M., Decrement of Transcriptome Level in Epithelial Tight Junction Claudin and Occludin as an Epithelial-Mesenchymal Transition Signature for Colorectal Cancer Biomarker, Galen Medical Journal, 11:e2350, (2022).
46. Lin C.H., Huang R.Y.J., Lu T.P., Kuo K.T., Lo K.Y., Chen C.H., Chen I.C., Lu Y.S., Chuang E.Y., Thiery J.P., Huang C.S., Cheng A.L., High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia, npj Breast Cancer, 7:88, (2021).
47. Chaudhary S., Appadurai M.I., Maurya S.K., Nallasamy P., Marimuthu S., Shah A., Atri P., Ramakanth C.V., Lele S.M., Seshacharyulu P., Ponnusamy M.P., Nasser M.W., Ganti A.K., Batra S.K., Lakshmanan I., MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR, Breast Cancer Research, 25:25, (2023).
48. Ratajczak-Wielgomas K., Grzegrzolka J., Piotrowska A., Matkowski R., Wojnar A., Rys J., Ugorski M., Dziegiel P., Expression of periostin in breast cancer cells, International Journal of Oncology, 51:1300-1310, (2017).
49. Yang J., Niu H., Huang Y., Yang K., A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis, PLoS One, 11:e0149185, (2016).
50. Fico F., Santamaria-Martínez A., TGFBI modulates tumour hypoxia and promotes breast cancer metastasis, Molecular Oncology, 14:3198-3210, (2020).
51. Fukui F., Hayashi S., Yamaguchi Y., Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy, The Journal of Steroid Biochemistry and Molecular Biology, 201:105698, (2020).
52. Zuo C., Liu Y., Wang Z., Chen H., Wang Y., Qiao Y., α-L-fucosidase isoenzymes (FUCA1/FUCA2) as prognostic markers in gliomas: a comprehensive study, BMC Cancer, 25:1511, (2025).
53. Bäumges H., Jelinek S., Lange H., Markmann S., Capriotti E., Häusser J.A., Ilse M.B., Braulke T., Deciphering α-L-Fucosidase Activity Contribution in Human and Mouse: Tissue α-L-Fucosidase FUCA1 Meets Plasma α-L-Fucosidase FUCA2, Cells, 14:1355, (2025).
54. Hu Y., Tang D., Zhang P., Prognostic and immunological role of alpha-L-fucosidase 2 (FUCA2) in hepatocellular carcinoma, Translational Cancer Research, 12:257-272, (2023).
55. Ren L., Yi J., Li W., Zheng X., Liu J., Wang J., Du G., Apolipoproteins and cancer, Cancer Medicine, 8:7032-7043, (2019).
56. Deng C.F., Zhu N., Zhao T.J., Li H.F., Gu J., Liao D.F., Qin L., Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential, Frontiers in Oncology, 12:803473, (2022).
57. Ossoli A., Wolska A., Remaley A.T., Gomaraschi M., High-density lipoproteins: A promising tool against cancer, Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1867:159068, (2022).
58. Pirro M., Ricciuti B., Rader D.J., Catapano A.L., Sahebkar A., Banach M., High density lipoprotein cholesterol and cancer: Marker or causative?, Progress in Lipid Research, 71:54-69, (2018).
59. Deangeli G., Spillantini M.G., Liò P., Proteomizer: Leveraging the Transcriptome-Proteome Mismatch to Infer Novel Gene Regulatory Relations, bioRxiv, (2025).
60. Chorlton S.D., Ten common issues with reference sequence databases and how to mitigate them, Frontiers in Bioinformatics, 4:1278228, (2024).
61. Bouadjenek M.R., Verspoor K., Zobel J., Literature consistency of bioinformatics sequence databases is effective for assessing record quality, Database (Oxford), (2017).